Diabetes drug price war heats up, making treatment more affordable
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
DelveInsight Business Research, LLP: Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
Zealand and Roche strike $5.3bn obesity treatment deal
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.